• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tofacitinib in Ulcerative Colitis - Second-Line Therapy, First-Rate Results.

作者信息

Harindranath Sidharth

机构信息

Department of Gastroenterology, Seth GS Medical College and KEM Hospital, Multi-Storey Building, 9thFloor, Parel, Mumbai, Maharashtra, 400012, India.

出版信息

Dig Dis Sci. 2024 Sep;69(9):3116-3118. doi: 10.1007/s10620-024-08589-1. Epub 2024 Aug 22.

DOI:10.1007/s10620-024-08589-1
PMID:39172324
Abstract
摘要

相似文献

1
Tofacitinib in Ulcerative Colitis - Second-Line Therapy, First-Rate Results.托法替布用于溃疡性结肠炎——二线治疗，一流疗效。
Dig Dis Sci. 2024 Sep;69(9):3116-3118. doi: 10.1007/s10620-024-08589-1. Epub 2024 Aug 22.
2
A case of Takayasu arteritis complicated by refractory ulcerative colitis successfully treated with tofacitinib.一例大动脉炎合并难治性溃疡性结肠炎患者经托法替布治疗成功
Rheumatology (Oxford). 2020 Jul 1;59(7):1773-1775. doi: 10.1093/rheumatology/kez580.
3
Efficacy of tofacitinib treatment in ulcerative colitis.托法替布治疗溃疡性结肠炎的疗效。
Gastroenterol Hepatol. 2019 Jun-Jul;42(6):403-412. doi: 10.1016/j.gastrohep.2019.03.002. Epub 2019 May 14.
4
Tofacitinib in ulcerative colitis - In the era of precision medicine'.托法替布治疗溃疡性结肠炎——在精准医学时代
Dig Liver Dis. 2024 May;56(5):909-910. doi: 10.1016/j.dld.2024.01.188. Epub 2024 Feb 2.
5
First Oral Drug for Moderate-To-Severe Ulcerative Colitis.首款用于中重度溃疡性结肠炎的口服药物。
Am J Nurs. 2018 Sep;118(9):22-23. doi: 10.1097/01.NAJ.0000544975.02936.da.
6
Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.托法替布治疗溃疡性结肠炎的诱导缓解和维持治疗。
N Engl J Med. 2017 May 4;376(18):1723-1736. doi: 10.1056/NEJMoa1606910.
7
Tofacitinib in ulcerative colitis.托法替布治疗溃疡性结肠炎。
Immunotherapy. 2016 May;8(5):495-502. doi: 10.2217/imt-2015-0031.
8
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry.托法替尼治疗溃疡性结肠炎：前瞻性荷兰克罗恩病和结肠炎倡议（ICC）注册研究结果。
Aliment Pharmacol Ther. 2020 May;51(9):880-888. doi: 10.1111/apt.15689. Epub 2020 Apr 1.
9
Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data.托法替布治疗溃疡性结肠炎的概况：基于证据的近期数据综述
Drug Des Devel Ther. 2019 Dec 2;13:4091-4105. doi: 10.2147/DDDT.S182891. eCollection 2019.
10
Successful remission with tofacitinib in a patient with refractory Takayasu arteritis complicated by ulcerative colitis.托法替布成功缓解一名合并溃疡性结肠炎的难治性大动脉炎患者的病情。
Ann Rheum Dis. 2020 Aug;79(8):1125-1126. doi: 10.1136/annrheumdis-2019-216606. Epub 2020 Mar 25.

引用本文的文献

1
Garlic Peel-Derived Phytochemicals Using GC-MS: Antioxidant, Anti-Inflammatory, and Anti-Apoptotic Effects in Ulcerative Colitis Rat Model.利用气相色谱-质谱联用技术分析大蒜皮中植物化学物质：对溃疡性结肠炎大鼠模型的抗氧化、抗炎和抗凋亡作用
Pharmaceuticals (Basel). 2025 Jun 27;18(7):969. doi: 10.3390/ph18070969.
2
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety.托法替布用于巴西溃疡性结肠炎的治疗：一项关于有效性和安全性的多中心观察性研究
BMC Gastroenterol. 2025 Mar 18;25(1):184. doi: 10.1186/s12876-025-03656-x.

本文引用的文献

1
Effect of Tofacitinib on One-Year Colectomy Risk in Anti-TNF Refractory Ulcerative Colitis: A Prospective Multicenter Italian Study.托法替尼治疗抗 TNF 难治性溃疡性结肠炎患者一年后结肠切除术风险的影响：一项前瞻性多中心意大利研究。
Dig Dis Sci. 2024 May;69(5):1785-1792. doi: 10.1007/s10620-024-08394-w. Epub 2024 Mar 26.
2
Histological healing induced by tofacitinib in ulcerative colitis: A multicentre study.托法替尼诱导溃疡性结肠炎组织学愈合：一项多中心研究。
Dig Liver Dis. 2024 Apr;56(4):613-621. doi: 10.1016/j.dld.2023.11.022. Epub 2023 Dec 7.
3
Tofacitinib Versus Oral Prednisolone for Induction of Remission in Moderately Active Ulcerative Colitis [ORCHID]: A Prospective, Open-Label, Randomized, Pilot Study.
托法替布与口服泼尼松龙治疗中度活动溃疡性结肠炎的诱导缓解疗效比较[ORCHID]：一项前瞻性、开放标签、随机、初步研究。
J Crohns Colitis. 2024 Feb 26;18(2):300-307. doi: 10.1093/ecco-jcc/jjad153.
4
Evolving Trends and Burden of Inflammatory Bowel Disease in Asia, 1990-2019: A Comprehensive Analysis Based on the Global Burden of Disease Study.亚洲炎症性肠病的演变趋势和负担，1990-2019：基于全球疾病负担研究的综合分析。
J Epidemiol Glob Health. 2023 Dec;13(4):725-739. doi: 10.1007/s44197-023-00145-w. Epub 2023 Sep 1.
5
Update on the epidemiology of inflammatory bowel disease in Asia: where are we now?亚洲炎症性肠病流行病学的最新情况：我们目前处于什么阶段？
Intest Res. 2022 Apr;20(2):159-164. doi: 10.5217/ir.2021.00115. Epub 2022 Apr 29.
6
Real-World Effectiveness and Safety of Tofacitinib in Patients With Ulcerative Colitis: Systematic Review With Meta-Analysis.托法替布治疗溃疡性结肠炎患者的真实世界有效性和安全性：系统评价与荟萃分析
Inflamm Bowel Dis. 2022 Jan 5;28(1):32-40. doi: 10.1093/ibd/izab011.
7
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis.在难治性溃疡性结肠炎患者中，托法替布的有效性和安全性的真实世界证据。
Dig Liver Dis. 2020 Mar;52(3):268-273. doi: 10.1016/j.dld.2019.10.003. Epub 2019 Nov 13.
8
Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies.炎症性肠病中的血栓栓塞事件和心血管死亡率：观察性研究的荟萃分析。
J Crohns Colitis. 2014 Jun;8(6):469-79. doi: 10.1016/j.crohns.2013.09.021. Epub 2013 Oct 30.